Cancer immunotherapy has attracted a lot of attention in recent years, but perhaps the greatest concentration of science in the field – backed with hundreds of millions of venture dollars – is under the roof of newly launched Juno Therapeutics. The start-up brings together two approaches to cancer immunotherapy and plans to develop the technologies in parallel, according to its lead investor.
The launch, unveiled Dec. 3, comes more than a year after Novartis AG took exclusive license of a prominent program at the University of Pennsylvania